Anke Hilse Maitland-van der Zee

Summary

Affiliation: Utrecht University
Country: The Netherlands

Publications

  1. ncbi request reprint Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, The Netherlands
    Atherosclerosis 163:213-22. 2002
  2. ncbi request reprint Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Acta Cardiol 61:327-31. 2006
  3. ncbi request reprint Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
    Am J Hypertens 18:1077-83. 2005
  4. ncbi request reprint A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Pharmacogenet Genomics 15:287-93. 2005
  5. ncbi request reprint Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant
    Bas J M Peters
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:631-6. 2008
  6. doi request reprint Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study
    Rianne M F van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Pharmacogenomics 13:1239-45. 2012
  7. pmc Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
    Bas J M Peters
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Atherosclerosis 217:458-64. 2011
  8. doi request reprint Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose
    Rianne M F van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
    Pharmacogenomics 13:1917-23. 2012
  9. ncbi request reprint Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction
    Diane B M A van Wieren-de Wijer
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands
    J Hypertens 27:61-8. 2009
  10. doi request reprint Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
    Talitha I Verhoef
    Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
    Pharmacogenomics 14:869-83. 2013

Collaborators

Detail Information

Publications55

  1. ncbi request reprint Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, The Netherlands
    Atherosclerosis 163:213-22. 2002
    ..Determining the genotype will not deny therapy to a subject, but will help in deciding the therapy that will suit the patient best...
  2. ncbi request reprint Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Acta Cardiol 61:327-31. 2006
    ..corrected] The influence ofApoE polymorphism on the efficacy of statins in lowering plasma lipids and lipoproteins and improving angiographic parameters was assessed...
  3. ncbi request reprint Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Centre, Houston, TX 77030, USA
    Am J Hypertens 18:1077-83. 2005
    ..The aim of this study was to characterize interindividual variation in glucose and lipid responses to hydrochlorothiazide and to identify demographic, environmental, and genetic predictors associated with this variation...
  4. ncbi request reprint A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Pharmacogenet Genomics 15:287-93. 2005
    ..To assess the influence of variations in multiple candidate genes on inter-individual variation in diastolic blood pressure (DBP) response to hydrochlorothiazide...
  5. ncbi request reprint Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant
    Bas J M Peters
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:631-6. 2008
    ..Therefore, we assessed whether the effectiveness of statins in reducing the risk of MI was modified by the GNB3 C825T polymorphism...
  6. doi request reprint Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study
    Rianne M F van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Pharmacogenomics 13:1239-45. 2012
    ..The EU-PACT trial investigates the added value of pretreatment genotyping for use of warfarin, phenprocoumon and acenocoumarol...
  7. pmc Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI
    Bas J M Peters
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Atherosclerosis 217:458-64. 2011
    ..In conclusion, ten SNPs were found to modify the effectiveness of statins in reducing the risk of MI in the UCP study. Five were also tested in the HVH study, but no interactions reached statistical significance...
  8. doi request reprint Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose
    Rianne M F van Schie
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands
    Pharmacogenomics 13:1917-23. 2012
    ..To investigate whether the phenprocoumon and acenocoumarol maintenance doses are influenced by genetic variations in GATA-4, a transcription factor of CYP2C9...
  9. ncbi request reprint Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction
    Diane B M A van Wieren-de Wijer
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands
    J Hypertens 27:61-8. 2009
    ..The Gly460Trp variant of the alpha-adducin gene has been associated with the salt-sensitive and diuretic responsive form of hypertension...
  10. doi request reprint Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
    Talitha I Verhoef
    Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
    Pharmacogenomics 14:869-83. 2013
    ..To investigate the cost-effectiveness of pharmacogenetic-guided phenprocoumon dosing versus standard anticoagulation care in Dutch patients with atrial fibrillation...
  11. ncbi request reprint Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 13:219-23. 2003
    ..18 (CI 1.01-10.03) in men. The apoE genotype is associated with discontinuation of statins. This suggests that subjects who are genetically prone to develop hypercholesterolemia show the highest risk of discontinuation of treatment...
  12. ncbi request reprint Reasons for non-response in observational pharmacogenetic research
    Diane B M A van Wieren-de Wijer
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 18:665-71. 2009
    ..We determined reasons for non-response and compared characteristics of non-responders and responders in a pharmacogenetic case-control study...
  13. ncbi request reprint Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht, The Netherlands
    Pharmacogenetics 14:53-60. 2004
    ..If other studies confirm that men with the DD genotype do not benefit from treatment with statins, screening for ACE genotype in men most likely will be a cost-effective strategy before initiating statin therapy...
  14. doi request reprint Patterns of asthma medication use: early asthma therapy initiation and asthma outcomes at age 8
    Ellen S Koster
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 19:991-9. 2010
    ..ICS and SABA prescription occurs especially in those who were more likely to develop signs of asthma at age 8...
  15. doi request reprint Uncontrolled asthma at age 8: the importance of parental perception towards medication
    Ellen S Koster
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pediatr Allergy Immunol 22:462-8. 2011
    ..The aim of this study was to identify determinants of uncontrolled asthma at age 8 in children participating in the PIAMA birth cohort study...
  16. doi request reprint Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction
    Bas J M Peters
    Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Pharmacogenomics 11:1065-76. 2010
    ..Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management...
  17. doi request reprint Limited agreement between current and long-term asthma control in children: the PACMAN cohort study
    Ellen S Koster
    Division of Pharmacoepidemiology and Clinical Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Pediatr Allergy Immunol 22:776-83. 2011
    ..To assess predictors of asthma control, we need firm outcome phenotypes. The aim of this study was to investigate the association between measurements of current and long-term asthma control...
  18. pmc The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 19:338-44. 2009
    ..Statins have been shown to influence the expression of coagulation factors II, V, VII, XII and XIII...
  19. ncbi request reprint Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose
    Rianne M F van Schie
    sion of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Drug Metabol Drug Interact 27:229-34. 2012
    ..Some case reports suggested that statins might affect the dose requirements of coumarins. The aim of the study was to investigate whether acenocoumarol and phenprocoumon maintenance doses are influenced by statin use...
  20. ncbi request reprint The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenetics 12:647-53. 2002
    ..The protective effect of statins on total mortality was not statistically significant, but did not seem to differ between subjects with different apoE genotypes...
  21. doi request reprint Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study
    Susanne J H Vijverberg
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
    Pediatr Allergy Immunol 23:529-36. 2012
    ..A high fraction of nitric oxide in exhaled breath (FeNO) has been suggested to be a marker of ongoing airway inflammation and poorly controlled disease in asthma. The usefulness of FeNO to monitor asthma control is still debated today...
  22. doi request reprint High agreement between parental reported inhaled corticosteroid use and pharmacy prescription data
    Ellen S Koster
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 19:1199-203. 2010
    ..This study was conducted to assess the validity of parental reported use of inhaled corticosteroids (ICS) in children...
  23. ncbi request reprint Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort
    Miranda J L Zuurhout
    Utrecht University, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherland gt
    Pharmacogenomics 14:1965-71. 2013
    ..Current evidence suggests that asthma patients with the ADRB2 Arg16 genotype have a poorer response to long-acting β2-agonists (LABA), but the results remain inconsistent...
  24. ncbi request reprint Pharmacogenetics of response to statins: where do we stand?
    Anke Hilse Maitland-van der Zee
    Human Genetics Center, Health Science Center at Houston, University of Texas, 1200 Hermann Pressler, Houston, TX 77030, USA
    Curr Atheroscler Rep 7:204-8. 2005
    ..Even though many studies have been performed, few results have been replicated. It is our contention that larger sample sizes and consideration of multiple genes are needed in the field of pharmacogenetics of statin response...
  25. doi request reprint Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study
    Ellen S Koster
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacoepidemiol Drug Saf 20:1064-72. 2011
    ..The aim of this study was to investigate factors associated with adherence in paediatric ICS users...
  26. doi request reprint Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarction
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, Utrecht, The Netherlands
    J Renin Angiotensin Aldosterone Syst 12:208-14. 2011
    ..This study investigated whether variation in the genes encoding for ACE, AGT and AGTR1 modifies the risk of myocardial infarction (MI) related to ACE inhibitors and AT II antagonists...
  27. doi request reprint Asthma therapy during the first 8 years of life: a PIAMA cohort study
    Mira G P Zuidgeest
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, 3508 TB Utrecht, The Netherlands
    J Asthma 47:209-13. 2010
    ..This study describes the formation of a longitudinal data set on asthma medication use and shows first results regarding the prevalence and incidence of medication use...
  28. ncbi request reprint Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
    Talitha I Verhoef
    Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
    Pharmacogenomics 13:1405-17. 2012
    ..We also explore the costs of anticoagulant care for the treatment of atrial fibrillation in these countries...
  29. doi request reprint Asthma medication use in infancy: determinants related to prescription of drug therapy
    Ellen S Koster
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht
    Fam Pract 28:377-84. 2011
    ..Little is known about factors that determine prescribing of asthma therapy in infancy...
  30. doi request reprint Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction
    Bas J M Peters
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands
    Pharmacogenet Genomics 20:766-74. 2010
    ....
  31. ncbi request reprint Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Sorbonnelaan 16, P O BOX 80082, 3508 TB, The Netherlands
    J Clin Epidemiol 57:237-42. 2004
    ..To obtain valid results, the definition of exposure in an observational study is critical. The objective of our study was to compare different exposure definitions for assessing the effectiveness of statins...
  32. doi request reprint Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment
    Diane B M A van Wieren-de Wijer
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, PO Box 80082, 3508 TB Utrecht, The Netherlands
    Pharm World Sci 31:158-64. 2009
    ..To describe the design, recruitment and baseline characteristics of participants in a community pharmacy based pharmacogenetic study of antihypertensive drug treatment...
  33. doi request reprint Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
    Rianne M F van Schie
    Study Coordinating Centre, Department of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
    Eur Heart J 32:1909-17. 2011
    ..To provide physicians with tools to estimate the patient's individual dose, we aimed to develop algorithms for PHE and ACE...
  34. pmc Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon
    Talitha I Verhoef
    Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht
    Br J Clin Pharmacol 77:626-41. 2014
    ..These genetic factors are used to develop dosing algorithms and can be used to predict the right coumarin dose. The effectiveness of this new dosing strategy is currently being investigated in clinical trials. ..
  35. pmc Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:651-6. 2008
    ..High homocysteine blood concentrations predispose to coronary artery disease and statins influence homocysteine levels...
  36. doi request reprint Methodological and statistical issues in pharmacogenomics
    Bas J M Peters
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    J Pharm Pharmacol 62:161-6. 2010
    ..Finally, conventional as well as several innovative approaches to the analysis of large pharmacogenomic datasets are proposed that deal with the issues of multiple testing and systems biology in different ways...
  37. doi request reprint Pharmacogenomic importance of pravastatin
    Bas Peters
    Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, The Netherlands
    Pharmacogenomics 9:1207-10. 2008
    ..This article reviews the most important studies conducted on the pharmacogenetics of pravastatin. Currently there is no evidence to advocate pharmacogenetic testing before initiating therapy...
  38. doi request reprint Genetic determinants of response to statins
    Bas J M Peters
    Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80082, 3508 TB, Utrecht, The Netherlands
    Expert Rev Cardiovasc Ther 7:977-83. 2009
    ..This article reviews the most important studies conducted on pharmacogenetics of statins. Currently, there is no evidence to advocate pharmacogenetic testing before initiating therapy...
  39. doi request reprint Asthma symptoms in pediatric patients: differences throughout the seasons
    Ellen S Koster
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    J Asthma 48:694-700. 2011
    ..The aim of this study was to describe seasonal patterns of asthma symptoms and asthma medication use in a cohort of pediatric asthma medication users and to study determinants of seasonal childhood asthma...
  40. ncbi request reprint Pharmacogenetics and the pharmaceutical industry
    Jan A M Raaijmakers
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, The Netherlands
    Curr Pharm Des 16:238-44. 2010
    ..In addition, collaborative efforts with academic partners are very much welcomed by the pharmaceutical industry and are expected to have a synergistic effect on progression in this field...
  41. doi request reprint Systems biology in pharmacogenomic research: the way to personalized prescribing?
    Ellen S Koster
    Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, PO Box 80082, 3508 TB Utrecht, The Netherlands
    Pharmacogenomics 10:971-81. 2009
    ..Therefore, in the future, a multidisciplinary systems-based approach will be necessary to deal with the bulk of the biological data that is available and, ultimately, to reach the goal of personalized prescribing...
  42. ncbi request reprint Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids
    Susanne Jh Vijverberg
    Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, Utrecht, The Netherlands and Department of Respiratory Medicine and Laboratory for Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Pharmacogenomics 15:799-806. 2014
    ..01, 95% CI: -0.06-0.08). Conclusion: Variation in GLCCI1 rs37972 genotype does not seem to affect ICS efficacy in north European asthmatic children. Original submitted 26 November 2013; Revision submitted 13 February 2014. ..
  43. pmc Pharmacogenetics of cardiovascular drug therapy
    Bas J M Peters
    Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Clin Cases Miner Bone Metab 6:55-65. 2009
    ..Therefore, new approaches are needed addressing issues and challenges such as the number of SNPs studied, study power, study design and application of new statistical methods in (pharmaco-)genetic analysis...
  44. doi request reprint Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort
    Ellen S Koster
    Utrecht University, Faculty of Science, Division of Pharmacoepidemiology and Pharmacotherapy, 3508 TB Utrecht, The Netherlands
    Pharmacogenomics 10:1351-61. 2009
    ..To investigate the effects of genetic variation on treatment response to asthma medication in children and to identify (profiles of) SNPs that characterize response phenotypes...
  45. ncbi request reprint Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharm World Sci 25:70-2. 2003
    ..The objective of this study was to determine whether pharmacy records of nitrate prescriptions could be used as a marker of angina pectoris...
  46. doi request reprint Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study
    Marjolein Geleedst-De Vooght
    Lusse Pharmacy, Utrecht, The Netherlands
    Drugs Aging 27:589-96. 2010
    ..However, several studies have shown prescription rates of statins to be significantly lower in the elderly than in younger populations...
  47. ncbi request reprint Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
    Rianne M F van Schie
    Utrecht University, Faculty of Science, Utrecht, The Netherlands
    Pharmacogenomics 10:1687-95. 2009
    ..The primary outcome measure is the percentage time in the therapeutic range for international normalized ratio. This report describes the design and protocol for the trial...
  48. doi request reprint A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives
    Talitha I Verhoef
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80 082, 3508 TB Utrecht, The Netherlands
    Pharmacogenomics 11:989-1002. 2010
    ..More reliable cost-effectiveness estimates need to become available before it is possible to recommend whether or not this strategy should be applied in clinical practice...
  49. doi request reprint Conference scene: initiatives on future biobanking in pharmacogenomics
    Susanne Vijverberg
    Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, Faculty of Science, Utrecht University, The Netherlands
    Pharmacogenomics 10:1135-8. 2009
    ..The European Association for Clinical Pharmacology and Therapeutics, GlaxoSmithKline and the Dutch Top Institute Pharma provided financial sponsorship...
  50. ncbi request reprint Workshop outcomes report: initiatives to establish a European Network of pharmacogenetics/genomics and progress
    Anke Hilse Maitland-van der Zee
    Division of Pharmacoepidemiology and Pharmacotherapy, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Eur J Pharm Sci 31:151-5. 2007
  51. pmc Pharmacogenomic insights into treatment and management of statin-induced myopathy
    Bas Jm Peters
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences UIPS, University of Utrecht, 3508 TB Utrecht, The Netherlands
    Genome Med 1:120. 2009
    ..Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy...
  52. ncbi request reprint Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels
    Aaron Isaacs
    Genetic Epidemiology Unit, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 92:2680-7. 2007
    ..The objectives of the current study were to characterize the effect of the hepatic lipase variant, and its interaction with the CETP variant, in terms of cholesterol levels, atherosclerosis, and risk of myocardial infarction (MI)...
  53. pmc Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study
    Anke Hilse Maitland-van der Zee
    School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
    Am Heart J 153:54-8. 2007
    ....
  54. ncbi request reprint Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism
    Anke Hilse Maitland-van der Zee
    Atherosclerosis 175:377-9. 2004
  55. ncbi request reprint Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?
    Tom Schalekamp
    Thromb Haemost 100:175-6. 2008